ATE213022T1 - Adenovirale vektoren für die gentherapie - Google Patents

Adenovirale vektoren für die gentherapie

Info

Publication number
ATE213022T1
ATE213022T1 AT96915934T AT96915934T ATE213022T1 AT E213022 T1 ATE213022 T1 AT E213022T1 AT 96915934 T AT96915934 T AT 96915934T AT 96915934 T AT96915934 T AT 96915934T AT E213022 T1 ATE213022 T1 AT E213022T1
Authority
AT
Austria
Prior art keywords
helper
gene therapy
adenoviral vectors
preparations
adenoviruses
Prior art date
Application number
AT96915934T
Other languages
English (en)
Inventor
Frank L Graham
Martina Anton
Michael A Rudnicki
Original Assignee
Frank L Graham
Martina Anton
Michael A Rudnicki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frank L Graham, Martina Anton, Michael A Rudnicki filed Critical Frank L Graham
Application granted granted Critical
Publication of ATE213022T1 publication Critical patent/ATE213022T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96915934T 1995-06-07 1996-06-07 Adenovirale vektoren für die gentherapie ATE213022T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/473,168 US5919676A (en) 1993-06-24 1995-06-07 Adenoviral vector system comprising Cre-loxP recombination
PCT/CA1996/000375 WO1996040955A1 (en) 1995-06-07 1996-06-07 Adenovirus vectors for gene therapy

Publications (1)

Publication Number Publication Date
ATE213022T1 true ATE213022T1 (de) 2002-02-15

Family

ID=23878471

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96915934T ATE213022T1 (de) 1995-06-07 1996-06-07 Adenovirale vektoren für die gentherapie

Country Status (8)

Country Link
US (2) US5919676A (de)
EP (1) EP0832267B1 (de)
JP (1) JP3492700B2 (de)
AT (1) ATE213022T1 (de)
AU (1) AU724161B2 (de)
CA (1) CA2220997C (de)
DE (1) DE69619110T2 (de)
WO (1) WO1996040955A1 (de)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US20020164782A1 (en) 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
US6730507B1 (en) 1993-06-24 2004-05-04 Merck & Co., Inc. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
US6080569A (en) * 1993-06-24 2000-06-27 Merck & Co., Inc. Adenovirus vectors generated from helper viruses and helper-dependent vectors
US20020136708A1 (en) * 1993-06-24 2002-09-26 Graham Frank L. System for production of helper dependent adenovirus vectors based on use of endonucleases
US7045347B2 (en) 1993-06-24 2006-05-16 Advec, Inc. Helper dependent adenovirus vectors based on integrase family site-specific recombinases
US20020146392A1 (en) * 1993-06-24 2002-10-10 Frank L. Graham Helper dependent adenovirus vectors based on site-specific recombinases
US6379943B1 (en) * 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
JP4216350B2 (ja) * 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター
US6964861B1 (en) 1998-11-13 2005-11-15 Invitrogen Corporation Enhanced in vitro recombinational cloning of using ribosomal proteins
US6720140B1 (en) * 1995-06-07 2004-04-13 Invitrogen Corporation Recombinational cloning using engineered recombination sites
US20060110798A1 (en) * 1995-06-07 2006-05-25 Graham Frank L Cells expressing recombinase useful for adenovirus vector production and control of gene expression
US6143557A (en) * 1995-06-07 2000-11-07 Life Technologies, Inc. Recombination cloning using engineered recombination sites
EP2322614A1 (de) 1995-06-07 2011-05-18 Life Technologies Corporation Rekombinatorische Klonierung unter Verwendung genmanipulierter Rekombinationsorte
IL160406A0 (en) 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
FR2737501B1 (fr) * 1995-07-31 1997-10-24 Transgene Sa Nouveaux virus auxiliaires pour la preparation de vecteurs viraux recombinants
DE19623203A1 (de) * 1995-11-24 1997-05-28 Max Planck Gesellschaft Virusvektor für den Transfer stabiler Episome
US20060088938A1 (en) * 1995-12-15 2006-04-27 Mitchell Lloyd G Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
US20020193580A1 (en) * 1995-12-15 2002-12-19 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20030027250A1 (en) * 1995-12-15 2003-02-06 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
WO1997025446A1 (en) * 1996-01-05 1997-07-17 Genetic Therapy, Inc. Recombinase-mediated generation of adenoviral vectors
AU2319497A (en) * 1996-03-07 1997-09-22 Regents Of The University Of California, The Helper-free, totally defective adenovirus for gene therapy
US6630346B1 (en) * 1996-06-20 2003-10-07 Merck & Co., Inc. Gene therapy for obesity
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
IL129222A0 (en) 1996-10-01 2000-02-17 Geron Corp Telomerase reverse transcriptase
US6475789B1 (en) * 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US5994132A (en) * 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
WO1998027217A1 (en) * 1996-12-16 1998-06-25 Eisai Co., Ltd. Method for preparing retrovirus vector for gene therapy
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US5851808A (en) 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
CA2283253A1 (en) * 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US7622549B2 (en) * 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US7413864B2 (en) * 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US20050013825A1 (en) * 1997-04-18 2005-01-20 Geron Corporation Vaccine containing the catalytic subunit of telomerase for treating cancer
WO1999014354A1 (en) 1997-09-19 1999-03-25 The Trustees Of The University Of The Pennsylvania Methods and vector constructs useful for production of recombinant aav
US7351578B2 (en) * 1999-12-10 2008-04-01 Invitrogen Corp. Use of multiple recombination sites with unique specificity in recombinational cloning
EP1025217B1 (de) * 1997-10-24 2006-10-04 Invitrogen Corporation Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
US20030124555A1 (en) * 2001-05-21 2003-07-03 Invitrogen Corporation Compositions and methods for use in isolation of nucleic acid molecules
JP2002507384A (ja) * 1997-11-25 2002-03-12 プリンストン ユニヴァーシティー アデノウイルスベクターの製造方法、それによって製造したベクターおよびその使用
DE19807265C2 (de) * 1998-02-20 2000-01-05 Centeon Pharma Gmbh Adenoviraler Transfervektor für den Gentransport einer DNA-Sequenz
US6337200B1 (en) * 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO2000012740A2 (en) 1998-08-28 2000-03-09 Duke University ADENOVIRUSES DELETED IN THE IVa2, 100K AND/OR PRETERMINAL PROTEIN SEQUENCES
US6303362B1 (en) 1998-11-19 2001-10-16 The Board Of Trustees Of The Leland Stanford Junior University Adenoviral vector and methods for making and using the same
CA2360796A1 (en) * 1999-02-04 2000-08-10 Merck & Co., Inc. Improved helper dependent vector system for gene therapy
WO2000049166A2 (en) * 1999-02-18 2000-08-24 Merck & Co., Inc. Production of helper dependent adenovirus vectors based on use of endonucleases
EP1173460B1 (de) * 1999-03-02 2009-09-16 Life Technologies Corporation Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
CA2366914C (en) 1999-03-05 2010-05-11 Merck & Co., Inc. Enhanced system for construction of adenovirus vectors
US20030215423A1 (en) * 1999-04-01 2003-11-20 Merck & Co., Inc. Gene therapy for obesity
EP1165817A1 (de) * 1999-04-06 2002-01-02 Merck & Co., Inc. Verwendung von helferabhängigen adenoviralen vektoren alternativer serotypen zur wiederholten vektorverabreichung
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
DE122008000035I1 (de) * 1999-04-06 2009-05-20 Wisconsin Alumni Res Found Rekombinante influenzaviren zur vakzinherstellung und gentherapie
CA2388337C (en) 1999-10-22 2013-01-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
NZ539430A (en) 1999-12-10 2006-09-29 Invitrogen Corp Use of multiple recombination sites with unique specificity in recombinational cloning
US6867022B1 (en) * 2000-01-21 2005-03-15 Regents Of The University Of Michigan Replication deficient adenovirus vectors and methods of making and using them
US7132277B1 (en) * 2000-01-31 2006-11-07 Merck & Co., Inc. Helper dependent vector system for gene therapy
JP4927290B2 (ja) 2000-04-14 2012-05-09 ウィスコンシン アルムニ リサーチ ファンデイション 変異イオンチャンネルタンパク質を含んで成るウイルス
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
US7244560B2 (en) * 2000-05-21 2007-07-17 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6716622B2 (en) * 2000-07-18 2004-04-06 Uab Research Foundation Tissue-specific self-inactivating gene therapy vector
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
AU2001288839A1 (en) * 2000-09-08 2002-03-22 The General Hospital Corporation Self-rearranging dna vectors
EP2336339A3 (de) 2000-09-25 2011-09-14 The Regents of the University of Michigan Herstellung viraler vektoren
EP1344536A4 (de) * 2000-11-24 2005-01-19 Chugai Pharmaceutical Co Ltd Verfahren zur regulierung der wirkung des expressionsprodukts eines in einen lebenden körper transferierten gens
US20040126774A1 (en) * 2001-01-08 2004-07-01 Mitchell Lioyd G. Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
CA2442144A1 (en) * 2001-03-26 2002-11-21 The Board Of Trustees Of The Leland Stanford Junior University A helper dependent adenoviral vector system and methods for using the same
JP2004531259A (ja) * 2001-04-19 2004-10-14 インヴィトロジェン コーポレーション 核酸分子の組換えクローニングのための組成物および方法
CA2451957A1 (en) * 2001-06-28 2003-01-09 Phenogene Therapeutiques Inc. Methods, vectors, cell lines and kits for selecting nucleic acids having a desired feature
WO2003025161A1 (en) * 2001-09-18 2003-03-27 Clontech Laboratories, Inc. Site-specific recombinase based method for producing adenoviral vectors
EP1516055A4 (de) * 2002-01-24 2007-08-08 Scripps Research Inst Faserschaftmodifikationen für effizientes zielen
US7399753B2 (en) * 2002-02-25 2008-07-15 Virxsys Corporation Trans-splicing mediated photodynamic therapy
ES2290449T3 (es) 2002-04-09 2008-02-16 Sanofi Pasteur Limited Acido nucleico de cea modificado y vectores de expresion.
JP2005536231A (ja) * 2002-05-08 2005-12-02 イントロン，インコーポレーテッド アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型ｒｎａトランススプライシングの使用
US8304233B2 (en) 2002-06-04 2012-11-06 Poetic Genetics, Llc Methods of unidirectional, site-specific integration into a genome, compositions and kits for practicing the same
JP2006500062A (ja) * 2002-09-27 2006-01-05 パウダージェクト リサーチ リミテッド 遺伝子発現のための核酸構築物
EP1579004B1 (de) * 2002-10-23 2010-06-16 VIRxSYS Corporation Screening-verfahren zur identifizierung wirksamer prä-trans-spleissmoleküle
US20040203133A1 (en) * 2003-01-07 2004-10-14 Anja Ehrhardt Helper dependent adenoviral vector system and methods for using the same
AU2004232992A1 (en) 2003-04-23 2004-11-04 Wisconsin Alumni Research Foundation Recombinant influenza viruses holding a mutation in a transmembrane protein gene
WO2005028615A2 (en) * 2003-06-26 2005-03-31 Invitrogen Corporation Methods and compositions for detecting promoter activity and expressing fusion proteins
CA2550583C (en) * 2003-10-08 2013-01-15 Sanofi Pasteur, Inc. Modified cea /b7 vector
WO2005054438A2 (en) 2003-12-01 2005-06-16 Invitrogen Corporation Nucleic acid molecules containing recombination sites and methods of using the same
EP1716165A4 (de) * 2004-01-23 2008-06-18 Virxsys Corp Expression von apoa-1 und varianten davon unter verwendung des spleissosom-vermittelten rna-trans-spleissens
US8053232B2 (en) * 2004-01-23 2011-11-08 Virxsys Corporation Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
US7968334B2 (en) * 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
US20060094110A1 (en) * 2004-07-30 2006-05-04 Mcgarrity Gerard J Use of spliceosome mediated RNA trans-splicing for immunotherapy
US20060134658A1 (en) * 2004-08-09 2006-06-22 Garcia-Blanco Mariano A Use of RNA trans-splicing for generation of interfering RNA molecules
PT2229956E (pt) 2004-09-13 2013-07-31 Genzyme Corp Contruções multiméricas
DE102004047492B4 (de) * 2004-09-23 2006-07-20 Jost-Werke Gmbh & Co. Kg Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
US7871795B2 (en) 2004-10-08 2011-01-18 Virxsys Corporation Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
EP1831365B1 (de) * 2004-10-08 2013-08-07 VIRxSYS Corporation Verwendung von rns trans-splicing zum antikörper gen transfer und zur antikörperherstellung
EA200701097A1 (ru) 2004-11-19 2007-10-26 Висконсин Эламни Рисёч Фаундэйшн Рекомбинантные векторы вируса гриппа с тандемными транскрипционными единицами
WO2007110695A2 (en) * 2005-10-13 2007-10-04 Bc Cancer Agency Modular genomes for synthetic biology and metabolic engineering
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
HUE040490T2 (hu) 2006-02-09 2019-03-28 Genzyme Corp Lassú intraventrikuláris szállítás
CA2647985C (en) 2006-03-31 2014-12-30 Warf-Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
ES2337973B8 (es) * 2008-05-16 2011-07-21 Proyecto De Biomedicina Cima, S.L. Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad.
EP2493912B1 (de) 2009-10-26 2020-07-29 Wisconsin Alumni Research Foundation Rekombinante influenzaviren mit hohem titer und erhöhter replikation in vero-zellen
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
JP6188728B2 (ja) 2012-02-07 2017-08-30 グローバル・バイオ・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｉｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 核酸送達の区画化方法ならびにその組成物および使用
WO2015009743A1 (en) 2013-07-15 2015-01-22 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
HK1225258B (en) 2013-08-08 2017-09-08 Global Bio Therapeutics, Inc. Clamping device for minimally invasive surgery
ES2739288T3 (es) 2013-09-13 2020-01-30 California Inst Of Techn Recuperación selectiva
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
KR102423442B1 (ko) 2015-12-11 2022-07-20 캘리포니아 인스티튜트 오브 테크놀로지 아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드
US11197925B2 (en) 2016-02-19 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
CA3060573A1 (en) 2017-04-21 2018-10-25 Baylor College Of Medicine Oncolytic virotherapy and immunotherapy
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
JP7655849B2 (ja) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
CN113966399A (zh) 2018-09-26 2022-01-21 加州理工学院 用于靶向基因疗法的腺相关病毒组合物
EP3914295A2 (de) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutationen zur verleihung von genetischer stabilität gegenüber zusätzlichen genen bei grippeviren
EP3921413A1 (de) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanisierte zelllinie
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
EP4060028A4 (de) * 2019-10-23 2023-10-04 Genenmed Co., Ltd. Auf helferplasmiden basierendes system zur produktion von gutless-adenoviren
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
CA3171935A1 (en) 2020-03-15 2021-09-23 Mahmoud ELJENDY Recombinant protein production in insects
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
US20240366681A1 (en) 2021-08-13 2024-11-07 Triovance Holding Llc A skin substitute composition and methods of producing and using the same
CN114410683B (zh) * 2022-01-12 2023-11-28 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的RIM3-RNAi及其应用
CN114369623B (zh) * 2022-01-12 2023-07-07 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的Synaptotagmin2-RNAi及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4920211A (en) * 1988-01-04 1990-04-24 Vanderbilt University Mutated adenovirus E1A gene for E1A promoter stimulation
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
AU1648092A (en) * 1992-03-19 1993-10-21 Cancer Research Campaign Technology Limited Defective recombinant adenoviruses expressing characteristic epstein-barr virus proteins
ATE404683T1 (de) * 1992-09-25 2008-08-15 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
EP0705344B8 (de) * 1993-06-24 2006-05-10 Advec Inc. Adenovirus vektoren für gentherapie
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
JP4216350B2 (ja) * 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター

Also Published As

Publication number Publication date
US5919676A (en) 1999-07-06
AU724161B2 (en) 2000-09-14
DE69619110D1 (de) 2002-03-21
US20010041173A1 (en) 2001-11-15
JP3492700B2 (ja) 2004-02-03
CA2220997A1 (en) 1996-12-19
EP0832267A1 (de) 1998-04-01
AU5889796A (en) 1996-12-30
CA2220997C (en) 2007-04-24
EP0832267B1 (de) 2002-02-06
DE69619110T2 (de) 2002-07-18
WO1996040955A1 (en) 1996-12-19
JPH11506334A (ja) 1999-06-08

Similar Documents

Publication Publication Date Title
DE69619110D1 (de) Adenovirale vektoren für die gentherapie
BG102612A (en) Complementary adenoviral vector systems and cellular lines
DE69535178D1 (de) Adenoviren-vektor systeme und zelllinien
NO982417D0 (no) Vektorer og fremgangsmÕter for genoverf°ring til celler
CA2213343A1 (en) Chimeric adenoviral fiber protein and methods of using same
PT797676E (pt) Vector adenoviral recombinante e metodos de utilizacao
WO1996007734A3 (en) Recombinant adenovirus comprising a chimeric penton base protein
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
CY1105440T1 (el) Κυτταρικες σειρες και κατασκευες χρησιμες στην παραγωγη ε1-διαγραμμενων αδενοϊων εν τη απουσια αδενοϊων ικανων αναπαραγωγης
DK1137758T3 (da) Fremgangsmåde og sammensætning til konservering af adenovira
DE69731611D1 (de) Eine Zusammensetzung enthaltend eine Detergenz und einen ein Tumorsuppressorgen kodierenden, adenoviralen Vektor
MXPA04004876A (es) Secuencias de acido nucleico y de aminoacido de adenovirus de simio, vectores que contienen los mismos y metodos de uso.
MX9705937A (es) Procedimiento de preparacion de genoma de adenovirus recombinantes.
CY1111931T1 (el) Φορεις αδενοϊων για την αγωγη νοσου
FI961666L (fi) Restenosiksen geeniterapia, jossa käytetään adenovirusvektoria
WO2000049168A3 (en) Helper adenovirus / helper-dependent adenovirus vector system based on site-specific recombinase activity
DE60031369D1 (de) Replikation -defektive baculoviren expressionssystem
HUP9802587A2 (hu) Glükózzal indukálható rekombináns virális vektor, ezt tartalmazó gyógyszerkészítmény és ezzel transzformált sejtek
WO2000012741A3 (fr) Systeme d'expression inductible
DE60038955D1 (de) AN DER OBERFLÄCHE VON KARZINOMZELLEN LOKALISIERTES COLLIGIN/HsP47
AU1099697A (en) Novel xylanases, genes encoding them, and uses thereof
EP0843006A3 (de) Rekombinante prostataspezifische Antigen-Vektoren und diese verwendende Assays
EP1185306A4 (de) Verwendung von viralen vektoren und geladenen molekülen für die gentherapie
CA2237059A1 (en) Targeted adenovirus vectors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties